NZ740842A - Device for therapeutic plasma exchange - Google Patents
Device for therapeutic plasma exchangeInfo
- Publication number
- NZ740842A NZ740842A NZ740842A NZ74084218A NZ740842A NZ 740842 A NZ740842 A NZ 740842A NZ 740842 A NZ740842 A NZ 740842A NZ 74084218 A NZ74084218 A NZ 74084218A NZ 740842 A NZ740842 A NZ 740842A
- Authority
- NZ
- New Zealand
- Prior art keywords
- line
- infusion
- zone
- replacement fluid
- plasma
- Prior art date
Links
- 210000002381 Plasma Anatomy 0.000 title claims abstract description 52
- 230000001225 therapeutic Effects 0.000 title claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 44
- 229940079593 drugs Drugs 0.000 claims abstract description 44
- 239000012530 fluid Substances 0.000 claims abstract description 44
- 238000001802 infusion Methods 0.000 claims abstract description 34
- 230000002429 anti-coagulation Effects 0.000 claims abstract description 21
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 21
- 230000036770 blood supply Effects 0.000 claims abstract description 5
- 210000004369 Blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 230000001276 controlling effect Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- 230000002572 peristaltic Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 101710027066 ALB Proteins 0.000 claims description 5
- 102100001249 ALB Human genes 0.000 claims description 5
- 229940050528 albumin Drugs 0.000 claims description 5
- 230000002441 reversible Effects 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 claims description 3
- 102000018358 Immunoglobulins Human genes 0.000 claims description 3
- 108060003951 Immunoglobulins Proteins 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 claims description 2
- 229960005348 Antithrombin III Drugs 0.000 claims description 2
- 102000004411 Antithrombin-III Human genes 0.000 claims description 2
- 108090000935 Antithrombin-III Proteins 0.000 claims description 2
- 102100009906 F7 Human genes 0.000 claims description 2
- 102100006624 F9 Human genes 0.000 claims description 2
- 229950003499 FIBRIN Drugs 0.000 claims description 2
- 108010076282 Factor IX Proteins 0.000 claims description 2
- 108010023321 Factor VII Proteins 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 229960000301 Factor VIII Drugs 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 229940012952 Fibrinogen Drugs 0.000 claims description 2
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- 229940012957 Plasmin Drugs 0.000 claims description 2
- 102000013566 Plasminogen Human genes 0.000 claims description 2
- 108010051456 Plasminogen Proteins 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 102100019017 VWF Human genes 0.000 claims description 2
- 229960004222 factor IX Drugs 0.000 claims description 2
- 229940012413 factor VII Drugs 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 230000000896 plasminic Effects 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 239000002753 trypsin inhibitor Substances 0.000 claims description 2
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 2
- 229960001134 von Willebrand factor Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 description 17
- 230000032258 transport Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 8
- 238000002616 plasmapheresis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 3
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Abstract
Device for therapeutic plasma exchange that comprises an extracorporeal circuit that comprises a blood supply line, a separating unit, a line for infusion of formed elements, a line for infusion of replacement fluid, a blood plasma line, an anticoagulant line and at least one independent line for therapeutic drugs. erapeutic drugs.
Description
Device for therapeutic plasma exchange
This application claims priority from Spanish patent application 201700336 filed 30 March 2017, the
entire contents of which are incorporated by reference.
DESCRIPTION
The present invention relates to the field of medical devices, and relates in particular to a device for
therapeutic plasma exchange that allows the administration of a therapeutic drug simultaneously with the
execution of the plasma exchange procedure and independently of the administration of a replacement
fluid.
Therapeutic plasma exchange (TPE) forms part of a larger group of techniques called plasmapheresis. In
plasmapheresis, blood is withdrawn from the human body and is processed in such a way that the
plasma is separated from the main formed elements of the blood (erythrocytes, leukocytes, platelets,
among others). At present, plasmapheresis is used for a variety of reasons, including transfusion,
donation of plasma for subsequent fractionation and obtaining blood derivatives, or the treatment of
diseases, which are treated by removing factors specific to the disease from the blood plasma.
TPE is a particular type of plasmapheresis indicated as treatment in many diseases, in which the plasma
that has been separated from the rest of the formed elements is discarded with the aim of removing the
harmful substances from the patient's blood. The formed elements that have been separated are usually
mixed with a liquid, known as replacement fluid, and returned to the patient. The commonest
replacement fluids include isotonic saline solutions, colloidal solutions of albumin, or fresh plasma,
among others. To avoid hypotension or peripheral oedema, it is preferable to supply a replacement fluid
based on a colloidal solution of albumin or fresh plasma capable of maintaining the oncotic pressure. In
most cases albumin at 4-5% in isotonic saline solution is the preferred option as replacement fluid,
because in contrast to fresh plasma, it is not specific to a particular blood group and presents less risk of
allergic reactions.
One of the main risks arising from the use of the TPE technique is due to the decrease in the
concentration of most of the plasma proteins, such as clotting factors, transport proteins, proteins of the
complement system, as well as antibodies, and in particular immunoglobulins G. For this reason, it is
often necessary to administer therapeutic drugs after completing the plasma exchange procedure, with
the aim, among others, of rebalancing the normal levels of the plasma proteins in the patient. Said
administration is usually by the intravenous, intramuscular or subcutaneous route, among others.
There is a need for TPE devices that allow one or more therapeutic drugs to be administered
simultaneously with execution of the plasma exchange procedure, in such a way that makes it possible,
40 among other things, to maintain the patient's levels of plasma proteins during the time that the plasma
exchange procedure takes, without having to wait for it to end to be rebalanced.
The TPE devices known in the prior art only allow a therapeutic drug to be administered if it is dissolved
in the replacement fluid. This involves various problems and their consequent risks to the patient's health,
among them the risk of manipulation of the replacement fluid or the impossibility of controlling the flow
rate of the therapeutic drug independently of the flow rate of the replacement fluid, among others.
Devices for plasmapheresis or plasma exchange are known in the prior art. For example, US patent
US5679245A discloses an apparatus for extracorporeal treatment of blood that comprises a filtration unit,
a primary circuit and a secondary circuit. Said patent also discloses an anticoagulant fluid line and a
replacement fluid line, which converge on the primary circuit.
Another drawback of the TPE devices known in the prior art is their large size and difficult portability,
meaning that the patient has to go to the medical centre to receive treatment. There is therefore a need
for TPE devices that overcome the drawbacks of the devices of the prior art.
The inventors of the present invention have developed a TPE device that overcomes the aforementioned
problems, and is surprising for several reasons. Among them, we may mention: the possibility of
administering a therapeutic drug simultaneously with the plasma exchange procedure and independently
of the administration of a replacement fluid, as well as improved portability.
In the present document, the term extracorporeal circuit refers to the combination of the various
independent lines of the TPE device.
In the present document, the term line or independent line refers to the combination of structural
elements selected from: liquid conveying means, liquid propelling means, liquid flow controlling means,
liquid storage means, among others, which jointly perform a particular function in the TPE device. The
term line does not refer to a minimum combination of structural elements, for example, in some cases a
line may be made up of conveying means and storage means, while in other cases a line may be made
up of conveying means, storage means, propelling means, among others. Moreover, several lines may
share one or more structural elements. Examples of lines are:
- Blood supply line or supply line: refers to the combination of structural elements that allows the patient's
blood to be conveyed from the zone of withdrawal to the inlet of the separating unit.
- Line for infusion of formed elements or formed elements line: refers to the combination of structural
elements that allows the formed elements to be conveyed from the outlet of the separating unit to the
infusion zone.
- Line for infusion of replacement fluid or replacement fluid line: refers to the combination of structural
elements that allows the replacement fluid to be conveyed from the replacement fluid container to the
40 infusion zone.
- Blood plasma line or plasma line: refers to the combination of structural elements that allows the blood
plasma to be conveyed from the plasma outlet of the separating unit to the blood plasma container.
- Anticoagulant line: refers to the combination of structural elements that allows the anticoagulant fluid to
be conveyed from the anticoagulant fluid container to the supply line.
- Line for infusion of therapeutic drug or line for therapeutic drug: refers to the combination of structural
elements that allows the therapeutic drug to be conveyed from the therapeutic drug container to the
infusion zone.
In the present document, the terms liquid conveying means or conveying means relate to elements such
as tubes, lines, pipes, among others, that allow liquid to be conveyed between two points through their
internal channel.
The terms liquid propelling means or propelling means refer to any element capable of transferring
energy to a liquid to achieve movement thereof through the conveying means. In the present invention,
said propelling means are preferably pumps and more preferably peristaltic pumps.
The terms liquid flow controlling means or flow controlling means refer to any element capable of
preventing/allowing or regulating the passage of liquid through the conveying means. In the present
invention, said flow controlling means are preferably valves and/or peristaltic pumps.
It will be obvious to a person skilled in the art that one and the same element may sometimes perform the
functions of propelling means and flow controlling means, for example a peristaltic pump may perform
both functions. It will also be obvious to a person skilled in the art that the propelling means and the flow
controlling means may be controlled electronically by a centralized control unit.
The terms liquid storage means, storage means or container are used synonymously in the present
invention to refer to any element that allows liquid to be contained within it and to be connected to a
conveying means. Said storage means are preferably: bottles, vials, plastic bags, among others, or
combinations thereof. It will be obvious to a person skilled in the art that the storage means may have an
outlet and/or an inlet, depending on the function that they perform in the extracorporeal circuit. It will also
be obvious to a person skilled in the art that the inlet and/or outlet of said storage means may be
controlled by flow controlling means.
The term therapeutic drug refers to any therapeutic liquid known by a person skilled in the art. Preferably,
said therapeutic drug comprises human plasma proteins selected from the group comprising albumin
(5-25%), αantitrypsin, von Willebrand factor, clotting factors such as factor VII, factor VIII and factor IX,
immunoglobulins, plasminogen, plasmin, antithrombin III, fibrinogen, fibrin, thrombin or combinations
thereof.
40 The term blood relates to whole blood, i.e. blood that contains all the formed elements of the blood such
as erythrocytes, leukocytes, platelets, etc., in addition to plasma.
The term blood plasma or plasma refers to the acellular liquid part of the blood.
The term separating unit refers to any device capable of separating the blood into its corresponding
cellular and acellular fractions. In the present document, said fractions are also called formed elements
and plasma, respectively.
Thus, the present invention discloses a TPE device that comprises an extracorporeal circuit that
comprises a blood supply line, a separating unit, a line for infusion of formed elements, a line for infusion
of replacement fluid, a blood plasma line, an anticoagulant line in addition to at least one independent
line for therapeutic drugs.
Said independent line for therapeutic drugs comprises at least one therapeutic drug container, conveying
means, propelling means and flow controlling means of said therapeutic drug. Preferably, said propelling
means of said independent line for therapeutic drugs are at least one peristaltic pump, more preferably
said peristaltic pump is a reversible peristaltic pump.
In another aspect of the present invention, the inventors have simplified a TPE device that comprises at
least one line for therapeutic drugs, with which it is possible to obtain a portable TPE device that
comprises at least one line for therapeutic drugs. Said simplification of the device has been achieved by
the sharing of structural elements (conveying means, propelling means, flow controlling means, among
others) by several of the lines known in the prior art (replacement fluid line, formed elements line, supply
line, among others) in addition to the at least one line for therapeutic drugs.
In one embodiment, the line for therapeutic drugs of the device of the present invention shares structural
elements with one or more of the other lines of the device. Preferably, said shared structural elements
are the conveying means, the propelling means and the flow controlling means. In a preferred
embodiment, said shared propelling means are at least one reversible peristaltic pump. In another
preferred embodiment said shared flow controlling means are a radial distributor.
The term radial distributor refers to a type of distributor such as that disclosed in Spanish Patent ES
2255772 B1 (Grifols Lucas, V.). Said distributor has several lines that communicate with a common
central point of the distributor and that may be put in communication with one another by the operation of
the flow controlling means integrated in said radial distributor. Said operation may be controlled
automatically by a centralized control unit.
The device of the present invention has a zone of withdrawal of the patient's blood and a zone of infusion
to the patient, said zones are also called simply withdrawal zone and infusion zone. In some
embodiments of the present invention, the withdrawal zone and the infusion zone are not coinciding
zones of the device, while in other embodiments the withdrawal zone and the infusion zone are
coinciding zones of the device.
In one embodiment of the present invention, the separating unit is a filter. In a preferred embodiment said
filter is a hollow-fibre filter.
In one embodiment of the present invention, the line for infusion of formed elements, the line for infusion
of replacement fluid and the line for therapeutic drugs comprise a bubble detector suitable for sending a
signal capable of stopping the action of the propelling means when there is an air bubble in the
conveying means of any of said lines.
In one embodiment of the present invention, the TPE device comprises means for measuring the
pressure in the lines.
In one embodiment of the present invention, the TPE device comprises conveying means that allow
communication between the replacement fluid line and the anticoagulant fluid line.
In one embodiment of the present invention the replacement fluid is an aqueous NaCl solution with a
concentration of 0.8 to 1% w/v.
The present invention is described in detail below in relation to the following figures, which do not limit the
scope of the present invention, in which:
Fig. 1 is a diagram of a first embodiment of the TPE device of the present invention.
Fig. 2 is a diagram of a second embodiment of the TPE device of the present invention.
Fig. 3 is a front view of a third embodiment of the TPE device of the present invention.
In a first embodiment, as can be seen in Fig. 1, the TPE device contains a supply line made up of the
tube and the pump . Said supply line extends from the withdrawal zone to the inlet of the
separating unit and transports whole blood from zone to the inlet of said separating unit. The
anticoagulant line is made up of the tube , the pump and the bag of anticoagulant, said
anticoagulant line extends from the bag to the supply line and transports anticoagulant fluid from said
bag to the supply line, where it is mixed with whole blood before the blood enters the separating unit
, where the patient's blood is separated into blood plasma and formed elements. The plasma line is
made up of the tube and the bag , said plasma line extends from the outlet of the separating
unit to the bag of blood plasma and transports said plasma from the outlet to the bag ,
where it is stored. The line for infusion of formed elements is made up of the tube , the bag of
formed elements, the tube and the pump , said formed elements line extends from the outlet
of the separating unit to the infusion zone and transports the formed elements separated by the unit
from the outlet to the bag , where they are stored in an initial step of the plasma exchange
process, and then transports the formed elements stored in the bag from said bag to zone .
The line for infusion of replacement fluid is made up of the tube , the pump , the bag of
replacement fluid, the tube that extends from the junction point to zone and the pump , said
40 replacement fluid line extends from the bag to zone and transports replacement fluid from said
bag to zone . Finally, the line for therapeutic drugs is made up of the tube , the pump ,
the tubes , and that converge at the junction point with the tube , the valves ,
and that regulate the passage of the therapeutic drugs from the vials , and and the
tube that extends from the junction point to zone , therefore the line for therapeutic drugs
extends from the vials , and to zone . Said line for therapeutic drugs transports the
therapeutic drugs from said vials , and to the infusion zone .
In a second embodiment, as can be seen in Fig. 2, the TPE device contains a withdrawal zone coincident
with an infusion zone, said zone is called withdrawal/infusion zone. The TPE device additionally
contains a supply line made up of the tube and the pump , said supply line extends from zone
to the inlet of the separating unit and transports whole blood from zone to the separating unit
. The anticoagulant line is made up of the tube , the pump and the bag of anticoagulant, said
anticoagulant line extends from the bag to the junction point and transports anticoagulant fluid
from the bag to the supply line, where it is mixed with the whole blood before said blood enters the
separating unit, where the blood is separated into blood plasma and formed elements. The plasma line is
made up of the tube and the bag of plasma, said plasma line extends from the outlet of the
separating unit to the bag and transports the blood plasma separated by the separating unit from the
outlet to the bag , where it is stored. The line for infusion of formed elements is made up of the
tube , the bag of formed elements, the tube , the tube that extends from the junction point
to zone and the pump , therefore said formed elements line extends from the outlet of the
separating unit to zone and transports the formed elements separated by the separating unit from the
outlet to zone . The line for infusion of replacement fluid is made up of the tube , the pump
, the bag of replacement fluid, the tube that extends from the junction point to zone and
the pump , therefore said replacement fluid line extends from the bag to zone and transports
replacement fluid from said bag to zone . Finally, the line for therapeutic drugs is made up of the
tube , the pump , the tubes , and that converge at the junction point with the
tube , the valves , and that regulate the passage of the therapeutic drugs from the vials
, and , the tube that extends from the junction point to zone and the pump ,
therefore the line for therapeutic drugs extends from the vials , and to zone , transporting
the therapeutic drugs from said vials to the infusion zone .
In a third embodiment, as can be seen in Fig. 3, the TPE device contains a withdrawal zone coincident
with an infusion zone and may be called withdrawal/infusion zone or venous access means. The
device of the embodiment also contains a blood supply line that is made up of the means , the Y-
connector , the tube , the Y-connector , the tube , the pump , the radial distributor
and the tube , therefore said supply line extends from zone to the inlet of the separating unit
and transports whole blood from zone to the separating unit . The anticoagulant line is made up
of a bag of anticoagulant, a tube , a Y-connector , a tube , a pump and a Y-connector
, therefore said line extends from the bag to the Y-connector , transporting anticoagulant fluid
from said bag to the supply line, where it is mixed with the whole blood before said blood enters the
separating unit , where the blood is separated into blood plasma and formed elements. The plasma
line is made up of the tube and the bag of plasma, said plasma line extends from the outlet
40 of the separating unit to the bag and transports the blood plasma from the outlet to the bag ,
where it is stored. The line for infusion of formed elements is made up of the tube , the bag of
formed elements, the tube , the radial distributor , the pump , the tube , the bubble
detector , the Y-connector , the tube , the Y-connector and the means , therefore the
formed elements line extends from the outlet of the separating unit to zone and transports the
separated formed elements from the outlet to zone . The line for infusion of replacement fluid is
made up of the bag of replacement fluid, the tube , the distributor , the tube , the pump
, the detector , the Y-connector , the tube , the Y-connector and the means ,
therefore the replacement fluid line extends from the bag to zone , transporting replacement fluid
from said bag to zone . The line for therapeutic drugs is made up of the vial of therapeutic
drug, the tube , the distributor , the tube , the pump , the detector , the Y-connector
, the tube , the Y-connector and the means , therefore said line for therapeutic drugs
extends from the vial to zone , transporting the therapeutic drug from the vial to zone .
Moreover, the TPE device of Fig. 3 also contains means for measuring pressures of the lines, said
means are made up of the tubes , and a unit for measuring pressures, which is not shown in the
figure. Finally, the device of Fig. 3 contains the tube that allows the anticoagulant line to be
connected to the replacement fluid line. As mentioned above, the distributor forms part of the prior
art, said distributor comprises a plurality of valves that allow communication of a plurality of tubes (for
example the tubes , , , , or ), so that by controlling said valves it is possible to allow
the passage of a particular liquid and prevent the passage of other liquids through said distributor.
Claims (16)
1. Device for therapeutic plasma exchange that comprises an extracorporeal circuit that comprises a blood supply line, a separating unit, a line for infusion of formed elements, a line for infusion of 5 replacement fluid, a blood plasma line and an anticoagulant line, characterized in that it further comprises at least one independent line for therapeutic drugs.
2. Device according to claim 1, characterized in that said independent line for therapeutic drugs comprises storage means, conveying means, propelling means and means for controlling the flow of said 10 therapeutic drug.
3. Device according to claim 2, characterized in that said propelling means of said line for therapeutic drugs are at least one peristaltic pump. 15
4. Device according to claim 3, characterized in that said peristaltic pump is a reversible peristaltic pump.
5. Device according to any one of the preceding claims, characterized in that said line for therapeutic drugs shares structural elements with one or more of the other lines of the device. 20
6. Device according to claim 5, characterized in that said shared structural elements are the conveying means, the propelling means and the flow controlling means.
7. Device according to claim 6, characterized in that the shared propelling means are at least one reversible peristaltic pump.
8. Device according to claim 6, characterized in that the shared flow controlling means are incorporated in a radial distributor.
9. Device according to any one of the preceding claims, characterized in that it has a blood withdrawal 30 zone and a zone of infusion to the patient, which coincide.
10. Device according to any one of the preceding claims, characterized in that the therapeutic drug comprises human plasma proteins selected from the group comprising albumin (5-25%), αantitrypsin, von Willebrand factor, clotting factors such as factor VII, factor VIII and factor IX, immunoglobulins, 35 plasminogen, plasmin, antithrombin III, fibrinogen, fibrin, thrombin or combinations thereof.
11. Device according to any one of the preceding claims, characterized in that the separating unit is a filter. 40
12. Device according to claim 11, characterized in that said filter is a hollow-fibre filter.
13. Device according to any one of the preceding claims, characterized in that the line for infusion of formed elements, the line for infusion of replacement fluid or the line for therapeutic drugs comprises a bubble detector.
14. Device according to any one of the preceding claims, characterized in that it comprises means for measuring pressures in the lines of the device. 5
15. Device according to any one of the preceding claims, characterized in that it comprises conveying means that allow the replacement fluid line to communicate with the anticoagulant line.
16. Device according to any one of the preceding claims, characterized in that the replacement fluid is an aqueous NaCl solution with a concentration of 0.8 to 1.0% w/v.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201700336 | 2017-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ740842A true NZ740842A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101857491B1 (en) | Tubing set having an improved gate for the connection of vials | |
US5098372A (en) | Methods and machine based on blood separation by filtration for plasma exchange treatment, plasma donation and cytapheresis such as platelet apheresis | |
ES2251404T3 (en) | UNINTERRUPTED FLOW PUMP METHOD AND APPLIANCE. | |
CN102711864B (en) | There is the pipe group of the door for connecting medicine bottle | |
US20120171658A1 (en) | Device and procedure for the manufacture of blood products | |
JP5690284B2 (en) | Dialysis machine, manifold and method for dialysis machine | |
JP2023506783A (en) | Extracorporeal blood processing system and method of employing batch processing | |
EP3381485B1 (en) | Device for therapeutic plasma exchange | |
NZ740842A (en) | Device for therapeutic plasma exchange | |
US11185621B2 (en) | Apparatus for carrying out an extracorporeal blood treatment | |
US10994066B2 (en) | Infusion line with a facility to promote mixing of an infusion solution with a further fluid, apparatuses and method | |
US20240001012A1 (en) | Solutions for continuous infusion of a drug administered via dialysis and dosing algorithm therefor | |
EP3603695A1 (en) | Blood purification device and priming method thereof | |
JPH0323866A (en) | Extracorporeal circulation circuit | |
JPH03162850A (en) | Blood transfusion system for animal |